Gilead Sciences, Inc.

Valuation Analysis

About the Company

Gilead Sciences, Inc. en bref

Gilead Sciences, Inc. (GILD) is currently trading at 108,00 € with a market capitalization of 134,1 Md €. The trailing P/E ratio stands at 16.84x, with a forward P/E of 12.8x. The 52-week range spans from 91,16 € to 137,26 €; the current price is 21.3% below the yearly high. Year-over-year revenue growth stands at +4.4%. The net profit margin stands at 30.99%.

💰 Dividende

Gilead Sciences, Inc. pays an annual dividend of 2,86 € per share, representing a yield of 2.65%. The payout ratio stands at 43.4%.

📊 Avis des analystes

28 analystes évaluent Gilead Sciences, Inc. (GILD) au consensus : Acheter. L'objectif de cours moyen est de 137,51 €, soit un potentiel de +27.32% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 106,47 € à 157,08 €.

Gilead Sciences, Inc. : la thèse d'investissement en détail

Gilead Sciences, Inc. (GILD) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 54.8% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 79.37%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 43.36% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.

Le scénario baissier

Revenue growth has slowed to just 4.4%, which is below nominal GDP — the business is no longer outgrowing the broader economy.

À surveiller

• The forward P/E of 12.8x is meaningfully below the trailing 16.84x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 27.32% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Gilead Sciences, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.